Хорватия - хорватский - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

bayer animal health gmbh, 51368 leverkusen, njemačka - enrofloksacin - otopina za injekciju - goveda, ovaca, koza, svinja

Хорватия - хорватский - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - haloperidoldekanoat - otopina za injekciju s produljenim oslobađanjem - 50 mg/ml - urbroj: 1 ml otopine za injekciju (1 ampula) sadržava 50 mg haloperidola u obliku haloperidoldekanoata

Европейский союз - хорватский - EMA (European Medicines Agency)

mabxience research sl - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Европейский союз - хорватский - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. za daljnje informacije o stanju čovjeka epidermalnog faktora rasta receptora 2 (her2), molimo pogledajte odjeljak 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. dodatne informacije o statusu her2 potražite u odjeljku 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Босния и Герцеговина - хорватский - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - bevacizumab - koncentrat za rastvor za infuziju - 25 mg/1 ml - 4 ml koncentrata za rastvor za infuziju sadrži: 100 mg bevacizumaba (25 mg/ml)

Босния и Герцеговина - хорватский - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - bevacizumab - koncentrat za rastvor za infuziju - 25 mg/1 ml - 16 ml koncentrata za rastvor za infuziju sadrži: 400 mg bevacizumaba (25 mg/ml)

Европейский союз - хорватский - EMA (European Medicines Agency)

norgine b.v. - željezni maltol - anemija, nedostatak željeza - antianemijski pripravci - feraccru prikazan kod odraslih za liječenje nedostatka željeza .

Европейский союз - хорватский - EMA (European Medicines Agency)

bayer animal health gmbh - iron(iii) ion, toltrazuril - толтразурил, kombinacije - svinje (prasadi) - za istovremenu prevenciju kliničkih simptoma кокцидиоза (kao što su proljev) novorođene prasadi na farmama sa potvrdio povijesti кокцидиоза uzrokovane cystoisospora суис i prevenciju anemije.

Хорватия - хорватский - HALMED (Agencija za lijekove i medicinske proizvode)

bionorica se, kerschensteinerstraße 11-15, neumarkt, njemačka - tekući ekstrakt timijanove zeleni (1 : 2-2,5) ekstrakcijsko otapalo: amonijeva otopina 10 % m/m : glicerol 85 % m/m : etanol 90 % v/v : voda (1 : 20 : 70 : 109) tekući ekstrakt bršljanovog lista (1 : 1) ekstrakcijsko otapalo: etanol 70 % v/v - sirup - urbroj: 1 ml (što odgovara 1,12 g) bronchipret sirupa sadrži: 168 mg tekućeg ekstrakta iz thymus vulgaris l. ili thymus zygis l., herba (timijanova zelen), ili mješavine obje vrste (1:2-2,5); ekstrakcijsko otapalo: amonijeva otopina 10 % m/m / glicerol 85 % m/m / etanol 90 % v/v / pročišćena voda (1/20/70/109) i 16,8 mg tekućeg ekstrakta iz hedera helix l., folium (bršljanov list) (1:1); ekstrakcijsko otapalo: etanol 70 % v/v

Хорватия - хорватский - HALMED (Agencija za lijekove i medicinske proizvode)

bionorica se, kerschensteinerstraße 11-15, neumarkt, njemačka - tekući ekstrakt timijanove zeleni (1 : 2-2,5) ekstrakcijsko otapalo: amonijeva otopina 10 % m/m : glicerol 85 % m/m : etanol 90 % v/v : voda (1 : 20 : 70 : 109) tekući ekstrakt bršljanovog lista (1 : 1) ekstrakcijsko otapalo: etanol 70 % v/v - sirup - urbroj: 1 ml (što odgovara 1,12 g) mucopret sirupa sadrži: 168 mg tekućeg ekstrakta iz thymus vulgaris l. ili thymus zygis l., herba (timijanova zelen), ili mješavine obje vrste (1:2-2,5); ekstrakcijsko otapalo: amonijeva otopina 10 % m/m / glicerol 85 % m/m / etanol 90 % v/v / pročišćena voda (1/20/70/109) i 16,8 mg tekućeg ekstrakta iz hedera helix l., folium (bršljanov list) (1:1); ekstrakcijsko otapalo: etanol 70 % v/v